Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : New drug symbols : AMGN save search
New Drug Delivery Systems Market 2022-2026 | Rising Prevalence Of Chronic Diseases to Boost Growth | Technavio
Published: 2022-03-02 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
BAX | $41.02 1.54% 0.0% 2.6M
|
Health Technology
|
| O: 0.28%
H: 0.54%
C: -0.33%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -2.63%
H: 0.9%
C: -0.3%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
new drug drug liver system disease growth drug delivery
New Drug Effective Against Lung Cancers Caused by Common Genetic Error
Published: 2021-06-04 (Crawled : 19:00) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
| Email alert
Add to watchlist
new drug genetic lung cancer cancer drug
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
Published: 2021-02-22 (Crawled : 14:12) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.59%
H: 1.51%
C: 0.49%
drug new drug psoriasis application plague
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
Published: 2020-12-16 (Crawled : 21:11) - prnewswire.com
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.3%
H: 0.99%
C: 0.93%
fda cancer drug lung cancer new drug application
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.